Estradiol-mediated Inflammation and Central Sensitization in the Pathophysiology of Endometriosis-associated Pelvic Pain
NCT07100782
This study is recruiting at 1 US site in 1 state, according to its ClinicalTrials.gov record last updated .
Summary
The purpose of this study is to better understand how hormone suppression with Relugolix Combination-Therapy (CT) affects pelvic pain, inflammation, and pain sensitivity in women with moderate-to-severe endometriosis associated pelvic pain.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Endometriosis
- Pelvic Pain
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 3
- Ages
- 18 to 49 years
- Sex
- Female
- Healthy volunteers
- Not accepted
- Sponsor
- University of Michigan
- Last updated on ClinicalTrials.gov
- February 18, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
Michigan · 1
- University of Michigan · Ann Arbor, MI
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.